Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mainz Biomed NV MYNZ

Healthcare Biotechnology
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of... see more

Recent & Breaking News (NDAQ:MYNZ)

Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany

GlobeNewswire April 27, 2023

Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal

GlobeNewswire April 26, 2023

Mainz Biomed Provides Full Year 2022 Financial Results

GlobeNewswire April 10, 2023

Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany

GlobeNewswire April 4, 2023

Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas

GlobeNewswire March 29, 2023

Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23

GlobeNewswire March 21, 2023

Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany

GlobeNewswire March 15, 2023

Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection

GlobeNewswire March 8, 2023

Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout "Blue" March 2023

GlobeNewswire March 1, 2023

Mainz Biomed to Appear on ClearThink IR's Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ET

GlobeNewswire February 28, 2023

Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program

GlobeNewswire February 21, 2023

Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK

GlobeNewswire February 15, 2023

Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert

GlobeNewswire January 18, 2023

Mainz Biomed Provides Year-End 2022 Corporate Review

GlobeNewswire January 3, 2023

Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

GlobeNewswire December 20, 2022

Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study

GlobeNewswire December 6, 2022

Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies

GlobeNewswire November 29, 2022

Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald's Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

GlobeNewswire November 22, 2022

Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert

GlobeNewswire November 15, 2022

Mainz Biomed Provides Third Quarter 2022 Update

GlobeNewswire November 2, 2022